Aurinia Pharmaceuticals (AUPH)
(Real Time Quote from BATS)
$5.64 USD
+0.03 (0.54%)
Updated Jul 8, 2024 03:18 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Aurinia Pharmaceuticals (AUPH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.14 | $15.00 | $6.00 | 80.75% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Aurinia Pharmaceuticals comes to $10.14. The forecasts range from a low of $6.00 to a high of $15.00. The average price target represents an increase of 86.74% from the last closing price of $5.43.
Analyst Price Targets (7 )
Broker Rating
Aurinia Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.57 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.57 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, four are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 57.14% and 28.57% of all recommendations. A month ago, Strong Buy made up 57.14%, while Buy represented 28.57%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/AUPH.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 2 | 2 | 2 | 2 | 1 |
Hold | 1 | 1 | 1 | 1 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.57 | 1.57 | 1.57 | 1.57 | 1.71 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/3/2024 | Bloom Burton & Company | David Martin | Hold | Moderate Buy |
5/2/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Stacy Ku | Strong Buy | Strong Buy |
3/1/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
2/23/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Strong Buy | Strong Buy |
2/16/2024 | Not Identified | Not Identified | Hold | Hold |
2/16/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.57 |
ABR (Last week) | 1.57 |
# of Recs in ABR | 7 |
Average Target Price | $10.14 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 98 of 252 |
Current Quarter EPS Est: | 0.01 |